Sharekhan

by BNP PARIBAS

Q4FY2021 Results Preview

Sector: Banking

Sector View

Private Banks	Positive		
PSU Banks	Neutral		

Our coverage universe

Companies	CMP (Rs)	Reco.	PT (Rs)
AU Small Finance	1,233	Buy	1,500
Axis Bank	688	Buy	900
Bank of Baroda	74	Hold	75
Bank of India	69	Hold	UR
City Union Bank	166	Buy	225
Federal Bank	79	Buy	95
HDFC Bank	1,447	Buy	1,810
ICICI Bank	578	Buy	770
IndusInd Bank	946	Buy	1,340
Kotak Mahindra Bank	1,792	Buy	2,130
Punjab National Bank	38	Hold	42
RBL Bank	216	Buy	UR
State Bank of India	285	Buy	460
UR - Under review			

Price chart



Banking

Sailing steady in testing times

Q4FY2021 quarter is expected to see steady earnings outlook because continued uptick in economic recovery and ease in liquidity conditions. However, post the Supreme Court's (SC) direction on recognition of non-performing assets (NPA), the street would watch closely on the disclosures on asset quality. Even though overall credit growth has improved from Q3 run-rate at ~7% y-o-y, we expect larger and well-capitalised banks (such as HDFC Bank, ICICI Bank, Axis Bank, and SBI) to report better advances growth and continue to gain market share. While the banking sector has seen improvement in systemic loan growth, performance is likely to be far from balanced. A few segments such as improvement in disbursements (healthy for segments such as retail, home, auto, LAP, and gold loans) are expected to lead growth, as they revert to pre-COVID levels. However, segments such as unsecured book and micro loans are likely to still remain soft as banks are likely to have been cautious about them. So far, overall asset-quality trends have fared better than expectations, led by sharp improvement in collection efficiency and a lower restructuring book, but the outlook because of the recent surge in COVID-19 cases would make management's commentary on growth and asset-quality outlook key to watch out for. With the SC's stay on NPA recognition being finally withdrawn, the overhang on the banking sector has gone away. We believe the focus shifts back on actual NPAs and the recovery process thereof. Management commentary on resumption of collections and recovery efforts will be keenly watched out. Q4 saw an increase in bonds yields, which could impact the treasury book and gains that banks were sitting on. We expect the quantum of treasury gains to decline on a sequential basis.

Most private banks (PBs) have been progressively de-risking their loan book by preferring to target the better-rated corporate segment and de-bulking of advances, which is likely to continue to be seen in Q4 as well. Most PBs had frontloaded their NPAs, which indicates that while slippages are likely to be elevated, credit cost is likely to be manageable for larger players. We expect performances of mid-size PBs to remain mixed, given asset-quality challenges (relatively high restructuring book, vulnerable segment, and low collection efficiency) as compared to larger peers. While many PBs have proactively provided for proforma NPAs, the revert in pandemic cases is likely to allow them maintain additional provision buffers, which will help limit the impact on profitability. For PSU banks (PSB), we believe credit growth is likely to be at or below system level growth (constrained by the need to conserve capital). We expect their legacy NPAs to keep the credit cost to remain elevated. We expect SBI to continue to be the best performer in the PSB space. For overall banks, we expect incrementally improved credit growth outlook for FY2022E/FY2023E and expect them to gradually wean off surplus liquidity on the balance sheet (which would reduce the drag on margins). We expect banks to continue to strengthen their balance sheets, helped by the recent capital raise (for both PSBs and PBs).

Outlook

We retain preference for PBs and SBI: The economy is showing signs of gradual return to recovery, which augurs well for long-term demand outlook. However, potential risks exist to economic recovery and global challenges (due to the pandemic), which are also present. However, this time the vaccination is likely to cushion the impact on the earnings front (especially on the asset-quality recognition part). Hence, we expect the gradual return to normalised business traction to be positive for banking companies. During Q4, we expect stronger PBs to show sequentially better growth, helped by healthy capital levels, which will provide support to margins. The recent spate of capital raising has been positive for balance sheet strengthening, and gradually reducing liquidity buffer will be positive support for margins and medium-term return ratios. We hope to see more clarity and granular information sharing on the book as lenders will share their strategy to align their portfolio and work with borrowers to recover loans. Agriculture is likely to be a relatively bright spot.

Valuation

We prefer large corporate/retail PBs and SBI among PSBs and see potential for them to gain market share as the situation normalises. Healthy market share gains and CASA ratio increase will be facilitators for improvement in return ratios.

Key risks

Due to resurgence of COVID 19, economic recovery may be prolonged. The economic distress may lead to further risk-off behaviour impacting profitability and growth outlook.

Leaders for Q4FY2021: HDFC Bank, ICICI Bank, and SBI

Laggards for Q4FY2021: BOI and PNB

Preferred Picks:

Private banks: ICICI Bank, HDFC Bank, Kotak Mahindra Bank, and AU Small Finance

Public sector bank: SBI



	Net Interest Income (Rs Cr)			PPoP (Rs Cr)			PAT (Rs Cr)					
Company	Q4FY21E	Q4FY20	YoY %	QoQ %	Q4FY21E	Q4FY20	YoY %	QoQ %	Q4FY21E	Q4FY20	YoY %	QoQ %
PSU Banks												
State Bank of India	29,751	22,766.9	30.7	3.2	18,235	15,733.8	15.9	5.6	6,540	3,580.8	82.6	27.4
Bank of Baroda	7,826	6,798.2	15.1	1.0	5,537	5,120.8	8.1	-1.0	1,268	506.6	150.2	19.5
Punjab National Bank	8,586	4,678.0	83.5	3.3	6,372	3,932.4	62.0	-0.3	948	(697.1)	NA	87.3
Bank of India	3,797	3,793.1	0.1	1.5	2,618	2,652.6	-1.3	-7.7	548	(3,571.4)	NA	1.3
Total PSU Banks	49,960	38,036	31.3	2.8	32,762	27,440	19.4	2.1	9,303	(181)	NA	28.5
Private Banks												
ICICI Bank	10,205	8,926.9	14.3	2.9	8,813	7,390.1	19.2	-0.1	5,100	1,221.4	317.6	3.3
Axis Bank	7,698	6,453.0	19.3	5.1	6,348	5,851.1	8.5	4.1	1,664	(1,387.8)	NA	49.0
HDFC Bank	16,655	15,203.4	9.5	2.1	14,895	12,958.2	14.9	-1.9	8,689	6,927.0	25.4	-0.8
Federal Bank	1,478	1,216.0	21.6	2.9	928	959.3	-3.3	-3.6	396	301.2	31.4	-2.0
IndusInd Bank	3,560	3,231.2	10.2	4.5	3,050	2,836.2	7.5	2.9	938	301.8	210.6	12.9
Kotak Mahindra Bank	4,214	3,559.7	18.4	5.2	3,404	2,725.3	24.9	10.4	2,103	1,266.6	66.1	13.5
RBL Bank	974	1,021.0	-4.6	5.5	845	751.9	12.4	15.4	163	114.4	42.9	133.7
City Union Bank	499	419.5	18.9	2.0	400	335.1	19.5	-12.6	167	(95.3)	NA	-2.0
AU Small Finance Bank	701	554.9	26.4	10.8	690	315.8	118.4	-21.0	277	122.3	126.1	-42.3
Total Private Banks	45,282	40,031	13.1	3.3	38,682	33,807	14.4	1.0	19,221	8,649	122.2	5.9

Source: Company, Sharekhan Research

Valuations

	CMP (Rs)	D 0.0	Target Price	BV	PS	P/BV		
Company		Reco/View	(Rs)	FY22E	FY23E	FY22E	FY23E	
PSU Banks								
State Bank of India	285	Buy	460	226.3	280.7	1.3	1.0	
Bank of Baroda	74	Hold	75	162.0	171.0	0.5	0.4	
Punjab National Bank	38	Hold	42	48.0	67.6	0.8	0.6	
Bank of India	69	Hold	UR	131.0	155.0	0.5	0.4	
Private Banks								
ICICI Bank	578	Buy	770	235.6	262.6	2.5	2.2	
Axis Bank	688	Buy	900	321.9	247.9	2.1	2.8	
HDFC Bank	1447	Buy	1810	398.1	452.5	3.6	3.2	
Federal Bank	79	Buy	95	87.4	97.3	0.9	0.8	
IndusInd Bank	946	Buy	1340	586.9	661.7	1.6	1.4	
Kotak Mahindra Bank	1792	Buy	2130	373.6	422.3	4.8	4.2	
RBL Bank	216	Buy	UR	246.7	271.5	0.9	0.8	
City Union Bank	166	Buy	225	91.4	107.8	1.8	1.5	
AU Small Finance	1233	Buy	1500	231.9	294.9	5.3	4.2	

Source: Company, Sharekhan Research UR: Price targets Under review

April 07, 2021 3



Q4FY2021 Banking earnings preview

Company-wise key expectations

Company-wise keg		1011						
Company	y-o-y (%)	q-o-q (%)	Comment					
Axis Bank								
NII	19.3	5.1	We expect loan growth at "8% y-o-y with a greater focus on the retail segment. likely to be sequentially flat (helped by improving funding cost benefits). We ex slippages to be lower on a q-o-q basis.					
PPOP	8.5	4.1						
PAT	(219.9)	49.0	stippages to be tower on a q-o-q basis.					
AU Small Finance E	Bank							
NII	26.4	10.8	We expect AUM growth to improve sequentially, and disbursements are expected					
PPOP	118.4	(21.0)	to normalise further. We expect NIM to be stable with a positive bias. Deposit					
PAT	126.1	(42.3)	momentum is likely to sustain.					
			We expect cost growth to pick-up as business activity resumes to earlier levels We expect provisions to sequentially elevate in the anticipated front loading c slippages; gains from Aavas stake sale to benefit PAT.					
City Union Bank								
NII	18.9	2.0	We expect cautious loan growth at mid-single digits during the quarter. Hence, NII					
PPOP	19.5	(12.6)	growth is likely to be similar to loan growth. We expect NIM to be flat. Impact of					
PAT	(274.7)	(2.0)	slowdown on SME portfolio and the collection/restructuring will be a key discussion area.					
FEDERAL BANK			uieu.					
NII	21.6	2.9	We expect loan growth to improve led by retail and SME businesses. We expect the					
PPOP		(3.6)	outlook to improve going forward. NIM is likely to be stable q-o-q with slippages					
	(3.3)		at <2% of loans. Focus would be on management commentary and impact on the					
PAT	31.4	(2.0)	SME portfolio of the bank.					
Indusind Bank								
NII	10.2	4.5	Operating parameters may remain subdued. Loan growth to be flat but strong					
PPOP	7.5	2.9	deposit growth and CASA recovery would help NIMs. We expect higher provisions					
PAT	210.6	12.9	to mute profit growth, mainly as sectors such as CV, rural, and select corporates, are expected to weaken. Management commentary on asset quality and credit cost outlook will be keenly monitored.					
ICICI BANK								
NII	14.3	2.9	We expect strong pre-provision operating profit (PPOP) growth due to improved					
PPOP	19.2	(0.1)	NII and advances traction. Loan growth to be at mid-teens and stable NIM. Asset					
PAT	317.6	3.3	quality to be largely stable. Credit costs likely to trend down on a q-o-q basis. Management commentary on asset quality and lockdown impact will be keenly monitored.					
HDFC Bank								
NII	9.5	2.1	We expect loan growth to be strong, a cautious outlook on growth continue. Retail					
PPOP	14.9	(1.9)	loan growth may be optically slower due to weak volume growth in auto, while					
PAT	25.4	(0.8)	growth in the unsecured portfolio may remain strong. Fee income growth to pick up. Healthy business traction expected.					
RBL Bank								
NII	(4.6)	5.5	We expect revenue growth to be slower than earlier, but deposit movement is likely					
PPOP	12.4	15.4	to be the bright spot. Management commentary and present position will be keenly					
PAT	42.9	133.7	watched out for. Moreover, conditions in retail and MFI business are dynamic and will be key monitorable for near-term business performance.					
State Bank of India	State Bank of India							
NII	30.7	3.2	We expect loan growth to be marginally better than industry levels at high single					
PPOP	15.9	5.6	digits with stable NIM (core) due to easing of cost of funds. Treasury income may					
PAT	6.0	27.4	be expected, and few corporate loan recoveries to benefit.					

Sharekhan Limited, its analyst or dependant(s) of the analyst might be holding or having a position in the companies mentioned in the article.

April 07, 2021



Know more about our products and services

For Private Circulation only

Disclaimer: This document has been prepared by Sharekhan Ltd. (SHAREKHAN) and is intended for use only by the person or entity to which it is addressed to. This Document may contain confidential and/or privileged material and is not for any type of circulation and any review, retransmission, or any other use is strictly prohibited. This Document is subject to changes without prior notice. This document does not constitute an offer to sell or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. Though disseminated to all customers who are due to receive the same, not all customers may receive this report at the same time. SHAREKHAN will not treat recipients as customers by virtue of their receiving this report.

The information contained herein is obtained from publicly available data or other sources believed to be reliable and SHAREKHAN has not independently verified the accuracy and completeness of the said data and hence it should not be relied upon as such. While we would endeavour to update the information herein on reasonable basis, SHAREKHAN, its subsidiaries and associated companies, their directors and employees ("SHAREKHAN and affiliates") are under no obligation to update or keep the information current. Also, there may be regulatory, compliance, or other reasons that may prevent SHAREKHAN and affiliates from doing so. This document is prepared for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. Recipients of this report should also be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The user assumes the entire risk of any use made of this information. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. We do not undertake to advise you as to any change of our views. Affiliates of Sharekhan may have issued other reports that are inconsistent with and reach different conclusions from the information presented in this report.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SHAREKHAN and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

The analyst certifies that the analyst has not dealt or traded directly or indirectly in securities of the company and that all of the views expressed in this document accurately reflect his or her personal views about the subject company or companies and its or their securities and do not necessarily reflect those of SHAREKHAN. The analyst and SHAREKHAN further certifies that neither he or his relatives or Sharekhan associates has any direct or indirect financial interest nor have actual or beneficial ownership of 1% or more in the securities of the company at the end of the month immediately preceding the date of publication of the research report nor have any material conflict of interest nor has served as officer, director or employee or engaged in market making activity of the company. Further, the analyst has also not been a part of the team which has managed or co-managed the public offerings of the company and no part of the analyst's compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this document. Sharekhan Limited or its associates or analysts have not received any compensation for investment banking, merchant banking, brokerage services or any compensation or other benefits from the subject company or from third party in the past twelve months in connection with the research report.

Either, SHAREKHAN or its affiliates or its directors or employees / representatives / clients or their relatives may have position(s), make market, act as principal or engage in transactions of purchase or sell of securities, from time to time or may be materially interested in any of the securities or related securities referred to in this report and they may have used the information set forth herein before publication. SHAREKHAN may from time to time solicit from, or perform investment banking, or other services for, any company mentioned herein. Without limiting any of the foregoing, in no event shall SHAREKHAN, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind.

Compliance Officer: Mr. Joby John Meledan; Tel: 022-61150000; email id: compliance@sharekhan.com; For any queries or grievances kindly email igc@sharekhan.com or contact: myaccount@sharekhan.com

Registered Office: Sharekhan Limited, 10th Floor, Beta Building, Lodha iThink Techno Campus, Off. JVLR, Opp. Kanjurmarg Railway Station, Kanjurmarg (East), Mumbai – 400042, Maharashtra. Tel: 022 - 61150000. Sharekhan Ltd.: SEBI Regn. Nos.: BSE / NSE / MSEI (CASH / F&O / CD) / MCX - Commodity: INZ000171337; DP: NSDL/CDSL-IN-DP-365-2018; PMS: INP000005786; Mutual Fund: ARN 20669; Research Analyst: INH000006183;

Disclaimer: Client should read the Risk Disclosure Document issued by SEBI & relevant exchanges and the T&C on www.sharekhan.com; Investment in securities market are subject to market risks, read all the related documents carefully before investing.